ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00839826
Recruitment Status : Completed
First Posted : February 10, 2009
Last Update Posted : December 17, 2014
Information provided by (Responsible Party):

Brief Summary:
Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE (up to 60 % without prophylaxis). The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but heparins have to be applied below the skin (subcutaneously). Additionally, there is a chance of developing a heparin-induced thrombocytopenia (decrease in platelets). Therefore, there is still a need for new agents which are safer and more efficient and which are easier to apply.The purpose of this study is to compare the safety and efficacy of BAY 59-7939 with the safety and efficacy of the licensed drug Enoxaparin. Enoxaparin, a so-called low molecular heparin, is approved and widely used in the area of thromboprophylaxis and will be given once daily subcutaneously.Another important purpose of the study is to find the optimal dose of BAY 59-7939 for thromboprophylaxis after hip replacement surgery. Therefore, there are several dose steps planned.

Condition or disease Intervention/treatment Phase
Thromboembolism Prevention Drug: Rivaroxaban (BAY59-7939) Drug: Enoxaparin Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 641 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement. ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
Study Start Date : December 2002
Actual Primary Completion Date : November 2003
Actual Study Completion Date : November 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hip Replacement
Drug Information available for: Rivaroxaban

Arm Intervention/treatment
Active Comparator: Arm 2 Drug: Enoxaparin
40 mg bid

Experimental: Arm 1 Drug: Rivaroxaban (BAY59-7939)
2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial

Primary Outcome Measures :
  1. The primary efficacy endpoint is a composite endpoint of: - Any DVT (proximal and/or distal) and - Non fatal PE and - Death from all causes. The primary endpoint will be evaluated 5 - 9 days after surgery. [ Time Frame: Assymptomatic DVT will be measured 5-9 days after surgery Symptomatc DVT , non-fatal PE and Death from all causes will be measured 41 days after surgery ]

Secondary Outcome Measures :
  1. Incidence of DVTs (total, proximal, distal) [ Time Frame: will be evaluated 5 - 9 days after surgery. ]
  2. Incidence of symptomatic VTEs [ Time Frame: 41 days after surgery ]
  3. The composite endpoint that results from the primary endpoint by using alternative definition of deaths (i.e. VTE related death) [ Time Frame: 41 days after surgery ]
  4. Incidence of symptomatic VTEs (total, PE, DVT) within 30 days after stop of treatment with the study drug. [ Time Frame: 41 days after surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male patients aged 18 years or above and postmenopausal female patients.
  • Patients scheduled for elective primary total hip replacement (cemented or non-cemented prosthesis).
  • Patients' written informed consent for participation after receiving detailed written and oral previous information to any study specific procedures.

Exclusion Criteria:

  • DVT or PE within the previous 6 months prior to study entry.
  • Myocardial infarction (MI) or cerebrovascular attack (CVA), TIA or ischaemic stroke within the last 6 months prior to study entry.
  • History of heparin-induced thrombocytopenia, allergy to heparins.
  • Intracerebral or intraocular bleeding within the last 6 months prior to study entry.
  • History of gastrointestinal disease with gastrointestinal bleeding within the last 6 months prior to the study.
  • History or presence of gastrointestinal disease which could result in an impaired absorption of the study drug
  • Amputation of one leg.Related to current symptoms or findings
  • Heart insufficiency NYHA III-IV.
  • Congenital or acquired haemorrhagic diathesis (PT INR/aPTT not within normal limits).
  • Thrombocytopenia (platelets < 50.000/µl).
  • Macroscopic haematuria.
  • Allergy to contrast media.
  • Severe hypertension (SBP > 200mmHg, DBP > 100 mmHg).
  • Impaired liver function (transaminases > 2 x ULN).
  • Impaired renal function (serum creatinine > 1.5 x ULN).
  • Active malignant disease.
  • Presence of active peptic ulcer or gastrointestinal disease with increased risk of gastrointestinal bleeding.
  • Body weight < 45 kg.
  • Drug- or alcohol abuse.
  • Related to current treatment

    • Therapy with oral anticoagulants (e.g. phenprocoumon, warfarin-sodium).
    • Therapy with acetylic salicylic acid or other thrombocyte aggregation inhibitors (e.g. clopidogrel, dipyridamole and ticlopidine) should be stopped one week before enrolment
    • Treatment with heparins or Factor Xa Inhibitors other than study medication.
    • All other drugs influencing coagulation, (exception: NSAIDs with half life < 17 hrs will be allowed).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00839826

  Show 41 Study Locations
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Bayer Identifier: NCT00839826     History of Changes
Other Study ID Numbers: 10942
First Posted: February 10, 2009    Key Record Dates
Last Update Posted: December 17, 2014
Last Verified: December 2014

Keywords provided by Bayer:
Prevention of Thromboembolism after total hip replacement

Additional relevant MeSH terms:
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action